Interferon-β_1a for the treatment of multiple sclerosis

Bibliography

• LUBLIN FD, REINGOLD SC et al.: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 46(4):907-911.
   PubMed Web of Science ®Google Scholar
• GOODIN DS, FROHMAN EM, GARMANY GP et al.: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practic Guidelines. Neurology (2002) 58(2):169-178. [Erratum in: Neurology (2002) 59(3):480].
   PubMed Web of Science ®Google Scholar
• ISAACS A, LINDEMANN J: Virus interference, I: the IFN. Proc. R. Soc. Med. (1957) 147:258-267.
   Google Scholar
• BORDEN EC, BALL LA: IFNs: biochemical, cell growth inhibitory and immunological effects. In: Progress in Hematology. Brown EB (Ed.), Grune & Stratton, New York, USA (1981):299-339.
   Google Scholar
• FRIEDMAN R: Interferons: a primer. Friedman R (Ed.), New York Academic Press, NY ,USA (1981).
   Google Scholar
• DE GRADO WF, WASSERMAN ZR, CHOWDR YV: Sequence and structural homologies among Type I and Type II IFNs. Nature (1982) 300:379-381.
   PubMed Web of Science ®Google Scholar
• RUNKEL L, MEIER W, BLAKE R et al.: Structural and functional differences between glycosylated and nonglycosylated forms of human IFN β (IFN-β). Pharm. Res. (1998) 15:641-649.
   PubMed Web of Science ®Google Scholar
• GLEZERMAN M, COHEN V, MOSHOVITZ M et al.: Placebo-controlled trial of topical IFN in labial and genital herpes. Lancet (1988) 1:150-152.
   PubMed Web of Science ®Google Scholar
• GAMBROSIER P, FRASCHINI P, LABIANCA P et al.: Beta-IFN in neoplastic patients suffering from herpes zoster or herpes simplex infections. Int. J. Immunother. (1987) III:237-243.
   Google Scholar
• KIRBY P: IFN in genital warts: much potential, modest progress. JAMA (1988) 259:570-572.
   PubMed Web of Science ®Google Scholar
• DINSMORE W, JORDAN J, O’MAHONEY C et al.: Recombinant human IFN-β in the treatment of condylomata acuminata. Int. J. STD AIDS (1997) 8:622-628.
   PubMed Web of Science ®Google Scholar
• CAPALBO M, PALMISANO L, BONINO F et al.: Intramuscular natural beta IFN in the treatment of chronic hepatitis B: a multicentre trial. Ital. J. Gastroenterol. (1994) 26:238-241.
   PubMedGoogle Scholar
• CHEMELLO L, SILVESTRI E, CAVALLETTO L et al.: Pilot study on the efficacy of intravenous natural β-IFN therapy in Italian patients with chronic hepatitis C and relation to the HCV genotype. Int. Hepatol. Commun. (1995) 3:237-243.
   Web of Science ®Google Scholar
• MILES SA, WANG H, CORTES E et al.: Beta-IFN therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann. Int. Med. (1990) 112:582-589.
   PubMed Web of Science ®Google Scholar
• MICHALEVICZ R, ADERKA D, FRISCH B et al.: IFN-beta induced remission in a hairy cell leukemia patient resistant to IFN-alpha. Leuk. Res. (1988) 12:845-851.
   PubMed Web of Science ®Google Scholar
• NAGAI M, ARAI T: Clinical effect of IFN on malignant brain tumours. Neurosurg. Rev. (1984) 7:55-64.
   PubMedGoogle Scholar
• JOHNSON DR, POBER JS: HLA class I heavy-chain gene promoter elements mediating synergy between tumor necrosis factor and interferons. Mol. Cell. Biol. (1994) 14(2):1322-1332.
   PubMed Web of Science ®Google Scholar
• YONG VW, CHABOT S, STUVE O, WILLIAMS G: IFN beta in the treatment of multiple sclerosis: mechanisms of action. Neurology (1998) 51:682-689.
   PubMed Web of Science ®Google Scholar
• HALL GL, COMPSTON A, SCOLDING NJ: Beta interferon and multiple sclerosis. Trends Neurosci. (1998) 20:63-67.
   Web of Science ®Google Scholar
• STUVE O, DOOLEY NP, UHM JH et al.: Interferon beta 1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. (1996) 40(6):853-863.
   PubMed Web of Science ®Google Scholar
• CALABRESI PA, PELFREY CM, TRANQUILL LR et al.: VLA expression on peripheral blood lymphocytes is down regulated after treatment of multiple sclerosis with IFN beta. Neurology (1997) 49:1111-1116.
   PubMed Web of Science ®Google Scholar
• MUNAFO A, TRICHARD-LUGAN II, NGUYEN TX et al.: Comparative farmacokinetics and farmacodynamics of recombimnant human interferon beta-1a after intramuscular and subcutaneous administration. Eur. J. Neurol. (1998) 5(2):187-193.
   PubMed Web of Science ®Google Scholar
• JACOBS L, COOKFAIR DL, RUDICK RA et al.: Intramuscular IFN beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. (1996) 39:285-294.
   PubMed Web of Science ®Google Scholar
• RUDICK RA, GOODKIN DE, JACOBS LD et al.: Impact of IFN beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology (1997); 49:358-363.
   PubMed Web of Science ®Google Scholar
• JACOBS LD, BECK RW, SIMON JH et al.: Intramuscular IFN beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS STUDY GROUP. N. Engl. J. Med. (2000) 343:898-904.
   Google Scholar
• CHAMPS STUDY GROUP: IFN beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am. J. Ophthalmol. (2001) 132(4):463-471.
   PubMed Web of Science ®Google Scholar
• COMI G, FILIPPI M, BARKHOF F et al.: Effect of early IFN treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 357:1576- 1582.
   PubMed Web of Science ®Google Scholar
• PRISMS STUDY GROUP: Randomised double-blind placebo-controlled study of IFN beta-1a in relapsing remitting multiple sclerosis. Lancet (1998) 352:1498-504.
   PubMed Web of Science ®Google Scholar
• CLANET M, RADUE EW, KAPPOS L et al.: A randomized, double-blind, dose-comparison study of weekly IFN beta-1a in relapsing MS. Neurology (2002) 59(10):1507-1517.
   PubMed Web of Science ®Google Scholar
• PANITCH H, GOODIN DS, FRANCIS G et al.: Evidence of IFN dose-response: European north american Comparative Efficacy; University of British Columbia MS/MRI research group. Randomized, comparative study of IFN beta-1a treatment regimens in MS: the EVIDENCE trial. The EVIDENCE Study Group. Neurology (2002) 59:1496-506.
   PubMed Web of Science ®Google Scholar
• SECONDARY PROGRESSIVEEFFICACY CLINICAL TRIAL OF RECOMBINANT INTERFERON-BETA-1A IN MS(SPECTRIMS STUDY GROUP): Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology (2001) 56(11):1496-1504.
   PubMed Web of Science ®Google Scholar
• COHEN J, CUTTER G, FISHER J:S. et al.: Benefit of interferon [Beta] 1a on MSFC progression in secondary progressive MS. Neurology (2002) 59:679-687.
   PubMed Web of Science ®Google Scholar
• KURTZKE JF: Rating neurologic impairments in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 33(11):1444-1452.
   PubMed Web of Science ®Google Scholar
• LEARY SM, MILLER DH, STEVENSON VL et al.: IFN beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology (2003) 60(1):44-51.
   PubMed Web of Science ®Google Scholar
• POLMAN C, BARKHOF F, KAPPOS L and the European oral IFN beta-1a in relapsing-remitting MS study group: oral IFN beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult. Scler. (2003) 9(4):342-348.
   PubMed Web of Science ®Google Scholar
• FILIPPI M, ROVARIS M, INGLESE M et al.: IFN beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 364(9444):1489-1496.
   PubMed Web of Science ®Google Scholar
• LI DK, PATY DW: Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo controlled study of interferon-beta1a in relapsing remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta 1a Subcutaneously in Multiple Sclerosis. Ann. Neurol. (1999) 46(2):197-206.
   PubMed Web of Science ®Google Scholar
• WALTHER EU, HOHLFELD R: Multiple sclerosis: side effects of IFN beta therapy and their management. Neurology (1999) 53:1622-1627.
   PubMed Web of Science ®Google Scholar
• DURELLI L, FERRERO B, OGGERO A et al.: Liver and thyroid function and autoimmunity during IFN beta-1b treatment for MS. The Betaferon® Safety Trial (BEST) study group. Neurology (2001) 57:1363-1370.
   PubMed Web of Science ®Google Scholar
• TORNATORE C, BARTLETT D: Tolerability of IFN beta -1b (Betaferon®/Betaseron®) can be significantly improved using both IFN-free needle and automated injection techniques. J. Neurol. (2002) 249(Suppl. 1):814.
   Google Scholar
• RUDICK RA, SIMONIAN NA, ALAM JA et al.: Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology (1998) 50:1266-1272
   PubMed Web of Science ®Google Scholar
• COOK SD, QUINLESS JR, JOTKOVITZ A, BEATON P: Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology (2001) 57:1080-1084.
   PubMed Web of Science ®Google Scholar
• VALLITU AM, HALMINEM M, PELTONIEMI J et al.: Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology (2002) 58:1786-1790.
   PubMed Web of Science ®Google Scholar
• BERTOLOTTO A, GILLI F, SALA A et al.: Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology (2003) 60:634-639.
   PubMed Web of Science ®Google Scholar
• DEISENHAMMER F, REINDL M, HARVEY J et al.: Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology (1999) 52:1239-1243.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1996) 47:889-894.
   PubMed Web of Science ®Google Scholar
• SORENSEN PS, ROSS C, CLEMMESEN KM et al.: Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet (2003) 362:1184-1191.
   PubMed Web of Science ®Google Scholar
• MALUCCHI S, SALA A, GILLI F et al.: Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology (2004) 62:2031-2037.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS, RICE GP, ALSOP JC: Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology (2005) 65:48-55.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, CLANET M, SANDBERG-WOLLHEIM M et al.: Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology (2005) 65:40-47.
   PubMed Web of Science ®Google Scholar
• SANDBERG-WOLLHEIM M, BEVER C, CARTER J et al.: Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis: EVIDENCE study. The EVIDENCE Study Group. J. Neurol. (2007) (In Press).
   Google Scholar
• OSTERBERG L, BLASCHKE T: Adherence to medication. N. Engl. J. Med. (2005) 353:487-497.
   PubMed Web of Science ®Google Scholar
• TREHARNE GJ, LYONS AC, HALE ED et al.: Compliance is futile but is concordance between rheumatology patients and health professionals attainable? Rheumatology (2006) 45:1-5.
   PubMed Web of Science ®Google Scholar
• FILIPPINI G, MUNARI L, INCORVAIA B et al.: Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet (2003) 361:545-552.
   PubMed Web of Science ®Google Scholar
• BERGER JR, KORALNIK IJ: Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N. Engl. J. Med. (2005) 353(4):414-416.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, TRABOULSEE A, CONSTANTINESCU C, Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology (2006) 67(6):944-953.
   PubMed Web of Science ®Google Scholar
• TREMLETT HL, OGER J: Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology (2003) 61(4):551-554.
   PubMed Web of Science ®Google Scholar
• O’CONNOR PW, GOODMAN A, WILLMER-HULME AJ et al.: Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Natalizumab Multiple Sclerosis Trial Group. Neurology (2004) 62(11):2038-2043.
   PubMed Web of Science ®Google Scholar
• BROD SA, NGUYEN M, HOOD Z, SHIPLEY GL: Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. (2006) 26(3):150-155.
   PubMed Web of Science ®Google Scholar